Vous êtes ici

Veritas Pharma Inc.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
VRT
Teneur de Marché: 
None Assigned
Indice CSE: 
Devise: 

Veritas Pharma Inc. (trading symbol CSE:VRT) is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).

Vous êtes ici

Veritas Pharma Inc. (VRT)

SEDAR Information

Information d'entreprise

Addresse
Suite 101 - 2386 East Mall, University of British Columbia
Vancouver, BC V6T 1Z3
Canada
Téléphone
778-968-6260
Courriel
info@seashoremedicine.com
Date d’inscription à la cote
Mardi, août 12, 2014
Relations avec les investisseurs
Dr. Luigi Franciosi, CEO
Vérificateur
Saturna Group Chartered Accountants LLP

Advertisement

Publicité

Capitalisation

Capitalisation: 
12,157,398
Réservé à l'émission: 
0

Company Officers

Peter McFadden , CEO
Peter McFadden , CFO

Communiqués de presse

Bulletins

08/02/2019

2019-0216 – Consolidation - Veritas Pharma Inc. (VRT)

Le 8 février/February 2019

Veritas Pharma Inc. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post-consolidation share for each ten (10) pre-consolidation common shares. 

As a result, the outstanding shares of the company will be reduced to approximately 12,157,399.

Advertisement

Publicité

Latest CSE News

Évènements à venir